Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Amgen's upcoming RANKL inhibitor denosumab will become the clinical gold standard by 2010. According to the new report entitled Osteoporosis: Turning Physician Insight into Projected Patient Share, the drug will replace Eli Lilly's Forteo as the clinical gold-standard therapy because of its improved safety and more convenient delivery relative to teriparatide.
"Clinical data thus far indicate that denosumab, unlike Forteo, is not associated with any life-threatening side effects, the safety end point most heavily weighted by surveyed endocrinologists, and it possesses a mild safety profile overall," said Decision Resources analyst Ramya Kollipara, Ph.D.
The report also finds that physician familiarity and experience with Novartis's Reclast, as well as the agent's infrequent dosing regimen, will result in strong market uptake.
About Osteoporosis: Turning Physician Insight into Projected Patient Share
Osteoporosis: Turning Physician Insight into Projected Patient Share covers the current and future state of the osteoporosis drug market. The report includes:
-- More than 3,000 physician responses that define drug attributes that drive prescription now and in the future. - Clinical end point tradeoffs that are most influential to physicians. - Areas of unmet need with highest potential. - Benchmark trial results for specific drug opportunities. - Patient share potential for emerging therapies and target product profiles. -- Decision Resources proprietary analysis of commercial factors that accelerate or constrain a drug's market potential. - Promotion: DTC spend, detailing intensity. - Reimbursement: formulary tier, prior approval restriction, quantity limits. - Labeling: black box warnings, approved patient segments, contraindications. - Competition: order of entry, pricing, generic entry, pipeline sales forecast. - Medical practice: decision trees, treating physician type, line of therapy. -- Comparisons of the key clinical attributes of current and emerging in the areas of efficacy, safety, and delivery. -- Analysis and supporting data that identifies the clinical "Gold Standard" now and over the next ten years. -- Key insights as to which clinical end points have the greatest influence on physician decision-making.
The report can be purchased by contacting Decision Resources. Members of the media may request a complimentary copy or an interview with an analyst.
About Decision Resources
Decision Resources, Inc., (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 email@example.com
SOURCE: Decision Resources, Inc.
Contact: Elizabeth Marshall of Decision Resources, Inc.,
Web site: http://www.decisionresources.com/